机构：[1]Laboratory of Mitochondria and Metabolism, Department of Burn and Reconstructive Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[2]Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[3]Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[4]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[5]National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院
Glioma is the most aggressive malignant tumor of the central nervous system, and most patients suffer from a recurrence. Unfortunately, recurrent glioma often becomes resistant to established chemotherapy and radiotherapy treatments. Immunotherapy, a rapidly developing anti-tumor therapy, has shown a potential value in treating recurrent glioma. Multiple immune strategies have been explored. The most-used ones are immune checkpoint blockade (ICB) antibodies, which are barely effective in monotherapy. However, when combined with other immunotherapy, especially with anti-angiogenesis antibodies, ICB has shown encouraging efficacy and enhanced anti-tumor immune response. Oncolytic viruses and CAR-T therapies have shown promising results in recurrent glioma through multiple mechanisms. Vaccination strategies and immune-cell-based immunotherapies are promising in some subgroups of patients, and multiple new tumor antigenic targets have been discovered. In this review, we discuss current applicable immunotherapies and related mechanisms for recurrent glioma, focusing on multiple preclinical models and clinical trials in the last 5 years. Through reviewing the current combination of immune strategies, we would like to provide substantive thoughts for further novel therapeutic regimes treating recurrent glioma.
基金：
This research was funded by Post-Doctor Research Project,West China Hospital, Sichuan
University, grant number 20HXBH170, and The APC was funded by the same project.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|2 区医学
小类|3 区肿瘤学
最新[2023]版：
大类|2 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]Laboratory of Mitochondria and Metabolism, Department of Burn and Reconstructive Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.[2]Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.
共同第一作者：
通讯作者：
通讯机构：[2]Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.[4]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.[5]National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China.
推荐引用方式(GB/T 7714)：
Pu Yi,Zhou Guanyu,Zhao Kejia,et al.Immunotherapy for Recurrent Glioma-From Bench to Bedside[J].Cancers.2023,15(13):doi:10.3390/cancers15133421.
APA：
Pu Yi,Zhou Guanyu,Zhao Kejia,Chen Yaohui&Shen Shensi.(2023).Immunotherapy for Recurrent Glioma-From Bench to Bedside.Cancers,15,(13)
MLA：
Pu Yi,et al."Immunotherapy for Recurrent Glioma-From Bench to Bedside".Cancers 15..13(2023)
